Back to mobile site

Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)

November 8, 2024 1:08 PM EST Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $32.00 price target on Pliant Therapeutics (NASDAQ: PLRX).The analyst commented: "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login